 Baird said that it has initiated coverage of TRACON Pharmaceuticals NASDAQ:TCON Inc with an outperform rating and a 10 price target. We see a high 70 probability of success for envafolimab, which is currently in a pivotal trial, and could be the first subcutaneously delivered PD-1 inhibitor approved in the US, the analysts said. 